157 related articles for article (PubMed ID: 24521249)
1. The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
Moreau P
Expert Rev Hematol; 2014 Apr; 7(2):265-90. PubMed ID: 24521249
[TBL] [Abstract][Full Text] [Related]
2. Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.
Landgren O; Sonneveld P; Jakubowiak A; Mohty M; Iskander KS; Mezzi K; Siegel DS
Leukemia; 2019 Sep; 33(9):2127-2143. PubMed ID: 31341235
[TBL] [Abstract][Full Text] [Related]
3. Future agents and treatment directions in multiple myeloma.
Ocio EM; Mitsiades CS; Orlowski RZ; Anderson KC
Expert Rev Hematol; 2014 Feb; 7(1):127-41. PubMed ID: 24350987
[TBL] [Abstract][Full Text] [Related]
4. Novel therapeutics in multiple myeloma.
Stewart AK
Hematology; 2012 Apr; 17 Suppl 1(0 1):S105-8. PubMed ID: 22507794
[TBL] [Abstract][Full Text] [Related]
5. Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Orlowski RZ
Semin Oncol; 2013 Oct; 40(5):634-51. PubMed ID: 24135408
[TBL] [Abstract][Full Text] [Related]
6. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.
Nijhof IS; van de Donk NWCJ; Zweegman S; Lokhorst HM
Drugs; 2018 Jan; 78(1):19-37. PubMed ID: 29188449
[TBL] [Abstract][Full Text] [Related]
7. Carfilzomib: a novel second-generation proteasome inhibitor.
Khan ML; Stewart AK
Future Oncol; 2011 May; 7(5):607-12. PubMed ID: 21568676
[TBL] [Abstract][Full Text] [Related]
8. Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world".
Mian HS; Fiala MA; Sanchez L; Vij R; Wildes TM
Ann Hematol; 2021 May; 100(5):1261-1266. PubMed ID: 33475778
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.
Jain S; Diefenbach C; Zain J; O'Connor OA
Core Evid; 2011; 6():43-57. PubMed ID: 21654882
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review.
Jindal N; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Nada R; Sethi J; Ahluwalia J; Malhotra P
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):426-431. PubMed ID: 32735793
[TBL] [Abstract][Full Text] [Related]
11. Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib.
Maruhashi T; Miki H; Sogabe K; Oda A; Sumitani R; Oura M; Takahashi M; Harada T; Fujii S; Nakamura S; Kurahashi K; Endo I; Abe M
Int J Hematol; 2024 Mar; 119(3):291-302. PubMed ID: 38252236
[TBL] [Abstract][Full Text] [Related]
12. Kyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma.
Raedler LA
Am Health Drug Benefits; 2016 Mar; 9(Spec Feature):93-6. PubMed ID: 27668053
[No Abstract] [Full Text] [Related]
13. Targeted treatments for multiple myeloma: specific role of carfilzomib.
Sugumar D; Keller J; Vij R
Pharmgenomics Pers Med; 2015; 8():23-33. PubMed ID: 25691814
[TBL] [Abstract][Full Text] [Related]
14. Current treatment landscape for relapsed and/or refractory multiple myeloma.
Dimopoulos MA; Richardson PG; Moreau P; Anderson KC
Nat Rev Clin Oncol; 2015 Jan; 12(1):42-54. PubMed ID: 25421279
[TBL] [Abstract][Full Text] [Related]
15. Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Wang M; Cheng J
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():24-30. PubMed ID: 25184233
[TBL] [Abstract][Full Text] [Related]
16. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Ashjian E; Redic K
J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma.
Berdeja JG; Hart LL; Mace JR; Arrowsmith ER; Essell JH; Owera RS; Hainsworth JD; Flinn IW
Haematologica; 2015 May; 100(5):670-6. PubMed ID: 25710456
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
McBride A; Klaus JO; Stockerl-Goldstein K
Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
[TBL] [Abstract][Full Text] [Related]
19. Novel drug combinations for the management of relapsed/refractory multiple myeloma.
Usmani SZ; Lonial S
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S71-7. PubMed ID: 25486960
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
